WALTHAM, Mass., Sept. 30, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on September 26, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 56,250 shares of the company's common stock, and an aggregate of 26,000 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $1.13 per share, which was the closing trading price of the company's common stock on the date of grant. The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more at prnewswire.comArdelyx, Inc. Reports Employment Inducement Grants
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.